| Dry Eye Syndromes
Xiidra vs Eysuvis
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Xiidra vs Eysuvis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEysuvis has a higher rate of injection site reactions vs Xiidra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eysuvis but not Xiidra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xiidra
Eysuvis
At A Glance
Ophthalmic
Twice daily
LFA-1 antagonist
Ophthalmic
Four times daily
Corticosteroid
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes Instill one drop twice daily (approximately 12 hours apart) into each eye using a single-use container; remove contact lenses prior to administration and reinsert 15 minutes after.
Dry Eye Syndromes Instill one to two drops into each eye four times daily for up to two weeks.
Contraindications
- Known hypersensitivity to lifitegrast or any other ingredient in the formulation
- Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
Adverse Reactions
Most common (>=5%) Instillation-site irritation, dysgeusia, reduced visual acuity
Common (1%-5%) Blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus, sinusitis
Postmarketing Hypersensitivity reactions including anaphylactic reaction, bronchospasm, respiratory distress, pharyngeal edema, swollen tongue, urticaria, allergic conjunctivitis, dyspnea, angioedema, allergic dermatitis, eye swelling, rash
Most common (>=5%) Instillation site pain
Serious Elevated intraocular pressure, optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing, secondary ocular infection from pathogens including herpes simplex, perforation of the globe
Pharmacology
LFA-1 antagonist; lifitegrast binds to integrin LFA-1 on leukocytes, blocking its interaction with ICAM-1 and inhibiting T-cell adhesion and migration, thereby reducing inflammation in dry eye disease.
Corticosteroid that inhibits the inflammatory response by suppressing edema, fibrin deposition, capillary dilation, leukocyte migration, fibroblast proliferation, and collagen deposition, likely via inhibition of prostaglandin production through glucocorticoid receptor binding.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xiidra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (11/12)
Eysuvis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
UnitedHealthcare
Xiidra
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (6/8)
Eysuvis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Xiidra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Eysuvis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xiidra.
No savings programs available for Eysuvis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XiidraView full Xiidra profile
EysuvisView full Eysuvis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.